A cystic fibrosis patient with the genotype
Cystic fibrosis (CF) is a severe, common, autosomal recessive disorder affecting about 1 in 2000 Caucasian newboms. The predominant mutation is a 3 base pair (bp) deletion in exon 10, AF508, which has an overall frequency of 68%.' The gene product 'cystic fibrosis transmembrane conductance regulator' (CFTR) is thought to affect the chloride transport through the cell membrane.' The model predicts two transmembrane, two ATP binding, and one regulatory domain. As the function of the protein still remains obscure, genotype-phenotype correlations might help in understanding the molecular mechanisms of this disease and might eventually contribute to the development of a therapy.
So far, eight other mutations clustered in exon 11 affecting the first nucleotide binding fold have been described.2' Kerem et aP and Guillermit et Schloesser, Arleth, Lenz, Bertele, Reiss including G551D/non-AF508, AI507/G551D was reported by Curtis et al,10 which is in contrast to the findings of Kerem et al. 2 Even two homozygous AF508 patients were PS.9 Pancreatic insufficiency can be used to assign severe alleles, whereas pancreatic sufficiency may change in patients with 'mild alleles'. Without further case reports on homozygotes and compound heterozygotes the dominant or recessive character of individual alleles cannot be determined.
Taking into account the phenotype found in homozygous AF508 patients, we favour the hypothesis that the CF mRNA of compound heterozygotes for the mutations described above is less stable or yields an unstable protein, which is rapidly degraded. The absence of a mutated regulator of chloride flux may result in a less severe phenotype than the presence of a defective regulator, for example, encoded by a AF508 allele. On the other hand, mutations at the genomic level may be 'bypassed' during transcript processing via exon skipping.
For the time being, definite conclusions cannot be drawn, as these hypotheses can only be tested by a functional activity assay, the demonstration of altered stability or processing of transcript or CFTR protein. 
